Regeneron Pharmaceuticals, Inc.
Common Stock · USD · NASDAQ
Price
$622.8
Cap
—
Earnings
—
30d Trend
-15.6%
33% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 53×Macro 0.99 (−1%)=52
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 65 (Greed) - Data: 80%
BRAIN47 HORIZON ANALYSIS
5-10 day swing — oversold bounce candidate
BRAIN47'S ASSESSMENT
I rate Regeneron Pharmaceuticals, Inc. at 52/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is quality at 74/100. I classify this as a defensive position with the strongest thesis on a short-term horizon.
PAST PERFORMANCE
1 MONTH
-9.3%
3 MONTHS
-20.4%
12 MONTHS
+3.2%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
5-10 day swing — oversold bounce candidate. Quality (74) and Momentum (53) are the primary strengths. I note that technical is the weakest area at 27/100 — this warrants monitoring. Historical volatility is moderate at 33%. I classify this as a defensive holding — stability characteristics and high business quality provide portfolio ballast.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.